FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2132909764> ?p ?o ?g. }

• W2132909764 endingPage "798" @default.
• W2132909764 startingPage "792" @default.
• W2132909764 abstract "ABSTRACT This study represents the first phase III trial of the safety, tolerability, and effectiveness of tafenoquine for malaria prophylaxis. In a randomized (3:1), double-blinded study, Australian soldiers received weekly malaria prophylaxis with 200 mg tafenoquine (492 subjects) or 250 mg mefloquine (162 subjects) for 6 months on a peacekeeping deployment to East Timor. After returning to Australia, tafenoquine-receiving subjects received a placebo and mefloquine-receiving subjects received 30 mg primaquine daily for 14 days. There were no clinically significant differences between hematological and biochemical parameters of the treatment groups. Treatment-related adverse events for the two groups were similar (tafenoquine, 13.4%; mefloquine, 11.7%). Three subjects on tafenoquine (0.6%) and none on mefloquine discontinued prophylaxis because of possible drug-related adverse events. No diagnoses of malaria occurred for either group during deployment, but 4 cases (0.9%) and 1 case (0.7%) of Plasmodium vivax infection occurred among the tafenoquine and mefloquine groups, respectively, up to 20 weeks after discontinuation of medication. In a subset of subjects recruited for detailed safety assessments, treatment-related mild vortex keratopathy was detected in 93% (69 of 74) of tafenoquine subjects but none of the 21 mefloquine subjects. The vortex keratopathy was not associated with any effect on visual acuity and was fully resolved in all subjects by 1 year. Tafenoquine appears to be safe and well tolerated as malaria prophylaxis. Although the volunteers' precise exposure to malaria could not be proven in this study, tafenoquine appears to be a highly efficacious drug for malaria prophylaxis." @default.
• W2132909764 created "2016-06-24" @default.
• W2132909764 creator A5008462094 @default.
• W2132909764 creator A5019258540 @default.
• W2132909764 creator A5031749778 @default.
• W2132909764 creator A5037242891 @default.
• W2132909764 creator A5045895492 @default.
• W2132909764 creator A5046769729 @default.
• W2132909764 creator A5072638559 @default.
• W2132909764 creator A5074853902 @default.
• W2132909764 creator A5077254510 @default.
• W2132909764 creator A5081877677 @default.
• W2132909764 creator A5088374546 @default.
• W2132909764 date "2010-02-01" @default.
• W2132909764 modified "2023-10-16" @default.
• W2132909764 title "Randomized, Double-Blind Study of the Safety, Tolerability, and Efficacy of Tafenoquine versus Mefloquine for Malaria Prophylaxis in Nonimmune Subjects" @default.
• W2132909764 cites W1833575339 @default.
• W2132909764 cites W1920717726 @default.
• W2132909764 cites W1992229319 @default.
• W2132909764 cites W1997649973 @default.
• W2132909764 cites W2012528514 @default.
• W2132909764 cites W2020299328 @default.
• W2132909764 cites W2045170643 @default.
• W2132909764 cites W2046986621 @default.
• W2132909764 cites W2075319878 @default.
• W2132909764 cites W2102664616 @default.
• W2132909764 cites W2109766515 @default.
• W2132909764 cites W2126190765 @default.
• W2132909764 cites W2134780685 @default.
• W2132909764 cites W2157838912 @default.
• W2132909764 cites W2166967003 @default.
• W2132909764 cites W2170788161 @default.
• W2132909764 cites W220685628 @default.
• W2132909764 cites W2247430354 @default.
• W2132909764 cites W3819217 @default.
• W2132909764 doi "https://doi.org/10.1128/aac.00354-09" @default.
• W2132909764 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2812156" @default.
• W2132909764 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19995933" @default.
• W2132909764 hasPublicationYear "2010" @default.
• W2132909764 type Work @default.
• W2132909764 sameAs 2132909764 @default.
• W2132909764 citedByCount "105" @default.
• W2132909764 countsByYear W21329097642012 @default.
• W2132909764 countsByYear W21329097642013 @default.
• W2132909764 countsByYear W21329097642014 @default.
• W2132909764 countsByYear W21329097642015 @default.
• W2132909764 countsByYear W21329097642016 @default.
• W2132909764 countsByYear W21329097642017 @default.
• W2132909764 countsByYear W21329097642018 @default.
• W2132909764 countsByYear W21329097642019 @default.
• W2132909764 countsByYear W21329097642020 @default.
• W2132909764 countsByYear W21329097642021 @default.
• W2132909764 countsByYear W21329097642022 @default.
• W2132909764 countsByYear W21329097642023 @default.
• W2132909764 crossrefType "journal-article" @default.
• W2132909764 hasAuthorship W2132909764A5008462094 @default.
• W2132909764 hasAuthorship W2132909764A5019258540 @default.
• W2132909764 hasAuthorship W2132909764A5031749778 @default.
• W2132909764 hasAuthorship W2132909764A5037242891 @default.
• W2132909764 hasAuthorship W2132909764A5045895492 @default.
• W2132909764 hasAuthorship W2132909764A5046769729 @default.
• W2132909764 hasAuthorship W2132909764A5072638559 @default.
• W2132909764 hasAuthorship W2132909764A5074853902 @default.
• W2132909764 hasAuthorship W2132909764A5077254510 @default.
• W2132909764 hasAuthorship W2132909764A5081877677 @default.
• W2132909764 hasAuthorship W2132909764A5088374546 @default.
• W2132909764 hasBestOaLocation W21329097642 @default.
• W2132909764 hasConcept C126322002 @default.
• W2132909764 hasConcept C141071460 @default.
• W2132909764 hasConcept C142724271 @default.
• W2132909764 hasConcept C168563851 @default.
• W2132909764 hasConcept C197934379 @default.
• W2132909764 hasConcept C203014093 @default.
• W2132909764 hasConcept C204787440 @default.
• W2132909764 hasConcept C27081682 @default.
• W2132909764 hasConcept C2776793103 @default.
• W2132909764 hasConcept C2777199930 @default.
• W2132909764 hasConcept C2777425658 @default.
• W2132909764 hasConcept C2778048844 @default.
• W2132909764 hasConcept C2778375690 @default.
• W2132909764 hasConcept C2778715236 @default.
• W2132909764 hasConcept C2779142074 @default.
• W2132909764 hasConcept C71924100 @default.
• W2132909764 hasConceptScore W2132909764C126322002 @default.
• W2132909764 hasConceptScore W2132909764C141071460 @default.
• W2132909764 hasConceptScore W2132909764C142724271 @default.
• W2132909764 hasConceptScore W2132909764C168563851 @default.
• W2132909764 hasConceptScore W2132909764C197934379 @default.
• W2132909764 hasConceptScore W2132909764C203014093 @default.
• W2132909764 hasConceptScore W2132909764C204787440 @default.
• W2132909764 hasConceptScore W2132909764C27081682 @default.
• W2132909764 hasConceptScore W2132909764C2776793103 @default.
• W2132909764 hasConceptScore W2132909764C2777199930 @default.
• W2132909764 hasConceptScore W2132909764C2777425658 @default.
• W2132909764 hasConceptScore W2132909764C2778048844 @default.
• W2132909764 hasConceptScore W2132909764C2778375690 @default.
• W2132909764 hasConceptScore W2132909764C2778715236 @default.
• W2132909764 hasConceptScore W2132909764C2779142074 @default.

• next